Annual report pursuant to Section 13 and 15(d)

Earnings (Loss) Per Common Share

v3.20.2
Earnings (Loss) Per Common Share
12 Months Ended
Jun. 30, 2020
Earnings (Loss) Per Common Share  
Earnings (Loss) Per Common Share

15.    Earnings (Loss) Per Common Share

Basic earnings (loss) per common share is computed by dividing the net income (loss) allocated to common stockholders by the weighted-average number of shares of common stock outstanding during the period. For purposes of calculating diluted earnings per common share, the denominator includes both the weighted-average number of shares of common stock outstanding during the period and the number of common stock equivalents if the inclusion of such common stock equivalents is dilutive. Dilutive common stock equivalents potentially include stock options and warrants using the treasury stock method. The following table summarizes the components of the earnings (loss) per common share calculation (in thousands, except per share amounts):

 

 

 

 

 

 

 

 

 

 

Years ended

 

 

June 30, 

 

    

2020

    

2019

Basic and diluted numerator:

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss attributable to iBio, Inc. stockholders

    

$

(16,439)

    

$

(17,593)

Deemed dividends – down round of Series A Preferred and Series B Preferred

 

 

(21,560)

 

 

 —

Preferred stock dividends – iBio CMO Preferred Tracking Stock

 

 

(261)

 

 

(260)

Net loss available to iBio, Inc. stockholders

 

$

(38,260)

 

$

(17,853)

 

 

 

 

 

 

 

Basic and diluted denominator:

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted-average common shares outstanding

 

 

62,795

 

 

18,926

 

 

 

 

 

 

 

Per share amount

 

$

(0.61)

 

$

(0.94)

 

In 2020 and 2019, the Company incurred net losses which cannot be diluted; therefore, basic and diluted loss per common share is the same. As of June 30, 2020, and 2019, shares issuable which could potentially dilute future earnings included were as follows.

 

 

 

 

 

 

 

 

Year Ended

 

 

June 30,

 

    

2020

    

2019

 

 

(in thousands)

Stock options

 

3,476

 

1,347

Series A Preferred

 

 —

 

4,430

Series B Preferred

    

28,925

    

6,428

Restricted stock units

 

41

 

 —

Shares excluded from the calculation of diluted loss per share

 

32,442

 

12,205